Rev Med Brux. 2006 Jan-Feb;27(1):29-38.
The present article reports the guidelines made by the European Lung Cancer Working Party (ELCWP) in April 2005 for the management of resectable non-small cell lung cancer (NSCLC). They aim to answer to the following eleven questions: 1) Is surgery the best therapy for a potentially resectable cancer? 2) How is complete resection defined? 3) Is a systematic lymph node dissection necessary during surgery? 4) Which place for radiotherapy after complete resection? 5) Should adjuvant or neoadjuvant chemotherapy be administered in case of clinical stage I or II? 6) Should adjuvant chemotherapy be administered in case of pathological stage I or II? 7) Is adjuvant therapy advisable after complete resection for pathological stage IIIA N2? If yes, what type: chemotherapy, radiotherapy, radiochemotherapy? 8) What are the indications for surgery after induction treatment in clinical stage IIIA or B? 9) In clinical stage IIIA or B, is preoperative induction therapy required, and if yes, what type? 10) What type of treatment is indicated after an incomplete surgical resection? 11) What is the best regimen for (neo) adjuvant chemotherapy?
本文报道了欧洲肺癌工作组(ELCWP)于2005年4月制定的关于可切除非小细胞肺癌(NSCLC)管理的指南。这些指南旨在回答以下十一个问题:1)手术是否是潜在可切除癌症的最佳治疗方法?2)如何定义完全切除?3)手术期间是否需要系统性淋巴结清扫?4)完全切除后放疗的位置在哪里?5)临床I期或II期病例是否应给予辅助或新辅助化疗?6)病理I期或II期病例是否应给予辅助化疗?7)病理IIIA期N2完全切除后辅助治疗是否可取?如果是,哪种类型:化疗、放疗、放化疗?8)临床IIIA期或B期诱导治疗后手术的指征是什么?9)在临床IIIA期或B期,是否需要术前诱导治疗,如果是,哪种类型?10)不完全手术切除后应采用何种治疗类型?11)(新)辅助化疗的最佳方案是什么?